Skip to search formSkip to main contentSkip to account menu

sofosbuvir

Known as: Sofosbuvir [Chemical/Ingredient], L-Alanine, N-[[P(S),2'R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl Ester, 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester 
An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral… 
National Institutes of Health

Related topics

Related topics

20 relations

Broader (1)

Antiviral Agents

Narrower (5)

GS-7977HarvoniPSI 7977Sovaldi
Hepatitis CIn BloodNucleoside Analogsagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Sofosbuvir as a potential option for the treatment of COVID-19
Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of… 
2017
2017
Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration
Data addressing real world effectiveness of direct acting antiviral agents in hepatitis C infected patients are now emerging… 
2017
2017
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES
Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre… 
Review
2017
Review
2017
Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis
It is unclear whether the efficacy and long‐term outcome of treating patients with hepatitis C virus (HCV)‐positive cirrhosis… 
2017
2017
The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society?
All‐oral regimens are associated with high cure rates in hepatitis C virus‐genotype 1 (HCV‐GT1) patients. Our aim was to assess… 
2016
2016
Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study
Background: Cenicriviroc (CVC), an oral chemokine receptor CCR2/5 antagonist, has potent anti-inflammatory and antifibrotic… 
Highly Cited
2015
Highly Cited
2015
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy… 
2015
2015
Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all… 
2014
2014
The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?
2013
2013
HCV treatment--no more room for interferonologists?
The landscape of therapy for hepatitis C virus (HCV) infection is changing rapidly. Until recently, the standard of care for HCV… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)